The company introduces an alternative approach by developing comprehensive B cell engineering services that replace the endogenous-coding antibodies of primary human B cells with antibodies that target specific viruses and tumors. Efficient expression of engineered antibodies in primary B cells under the control of endogenous regulatory elements has been observed. Engineered cells also maintain normal antibody expression and secretion.